Chester County News and Community Website
SPRING HOUSE, PA — Johnson & Johnson (NYSE: JNJ) reported that its oral psoriasis treatment ICOTYDE (icotrokinra) maintained skin clearance through 112 weeks in a Phase 3 clinical study, providing …
Johnson & Johnson Psoriasis Drug Sustains Clearance at Two Years Read More SPRING HOUSE, PA — Johnson & Johnson (NYSE: JNJ) reported that adolescents with generalized myasthenia gravis maintained improvements in daily function and muscle strength through two years of IMAAVY treatment, …
J&J’s IMAAVY Maintains Gains in Two-Year Adolescent Study Read More
RADNOR, PA — Mineralys Therapeutics, Inc. (Nasdaq: MLYS) will present Phase 3 data this month examining whether its experimental hypertension drug lorundrostat reduced both blood pressure and albuminuria in patients …
Mineralys Extends Lorundrostat Focus to Kidney Disease Read More
PHILADELPHIA, PA — Century Therapeutics, Inc. (NASDAQ: IPSC) remains on track to seek U.S. clearance in the fourth quarter to begin clinical testing of CNTY-813, its experimental type 1 diabetes …
Century Advances Diabetes Cell Therapy Toward FDA Filing Read More
NEW HOPE, PA — Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) has exceeded its enrollment target in a pivotal hypertension trial conducted with Medtronic, moving the companies toward primary endpoint data …
Orchestra BioMed Completes Enrollment in Hypertension Trial Read More
PHILADELPHIA, PA — Medicus Pharma Ltd. is seeking U.S. Food and Drug Administration approval for a redesigned late-stage development plan that could cut enrollment in its Teverelix advanced prostate cancer …
Medicus Seeks FDA Path to Cut Teverelix Trial by 60% Read More
MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) has secured provisional approval and priority designation in The Bahamas for OCU400, creating a pathway to provide its investigational gene therapy to retinitis …
Ocugen Wins Bahamas Priority Path for OCU400 Gene Therapy Read More
CHESTERBROOK, PA — Persevere Therapeutics has dosed the first patient in a Phase 2a trial of misetionamide at the University of Pennsylvania’s Abramson Cancer Center, moving the experimental MYC inhibitor …
Persevere Begins Phase 2a Ovarian Cancer Trial at Penn Read More
YARDLEY, PA — Jubilant Therapeutics reported early clinical activity for JBI-802 in a Phase 1/2 trial of patients with myeloproliferative neoplasms, with dose-responsive platelet reductions observed across several disease subtypes …
Jubilant Reports Early Platelet Reductions With JBI-802 Read More
PLYMOUTH MEETING, PA — Adverse-event reports for Braeburn’s Brixadi remained low and relatively stable during its first 18 months on the U.S. market, according to a company-funded study examining federal …
Braeburn Study Finds Low Adverse-Event Reporting for Brixadi Read More